



FAXED
12/7/99

SCIENTIFIC THERAPEUTICS
INFORMATION, INC

505 Morris Avenue
Springfield, New Jersey
07081

(973) 376-5655 telephone
(973) 376-0611 fax 1
(973) 376-5367 fax 2

<http://www.stimedinfo.com>
E-mail: stat@stimedinfo.com

December 7, 1999

Jim McCafferty
Director, Clinical Scientists
SmithKline Beecham Pharmaceuticals
1250 S Collegeville Rd UP 4410
PO Box 5089
Collegeville, PA 19426-0989

RE: PUBLICATION STATUS - PAROXETINE ADOLESCENT DEPRESSION STUDY

Dear Dr McCafferty:

The purpose of this letter is to inform you of the publication status of this study and to outline next steps.

Dr Keller submitted the manuscript to *JAMA* in early August, 1999. The journal elected not to publish the paper and notified Dr Keller in November. In a conference call in November involving Drs Keller, Ryan, and Strober and Jim McCafferty, the action plan itemized below was agreed upon:

1. Sally Laden and Jim McCafferty will summarize the reviewers' extensive comments and draft a memo outlining the changes to be made.
2. This memo will be circulated to all authors for their review and approval.
3. The current draft will be revised and circulated to all authors for review and approval.
4. The revised manuscript will be submitted to *American Journal of Psychiatry*.

Resubmitting this manuscript is our top priority, and we will be asking for rapid review when we send materials to the authors.

Thank you for your attention to this matter. Please do not hesitate to contact me (203/272-9750), Jim MacCafferty (610/917-4705), or Marty Keller (401/455-6430) if you have questions or require additional information.

Sincerely,

Sally K. Laden, MS
Associate Editorial Director

cc: Martin B. Keller, MD, Barry Brand, .1301

PAR000757483